✦ LIBER ✦

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

✍ Scribed by Gianluca Masi; Fotios Loupakis; Lisa Salvatore; Lorenzo Fornaro; Chiara Cremolini; Samanta Cupini; Andrea Ciarlo; Francesca Del Monte; Enrico Cortesi; Domenico Amoroso; Cristina Granetto; Gabriella Fontanini; Elisa Sensi; Cristiana Lupi; Michele Andreuccetti; Alfredo Falcone

Book ID: 117785431
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 269 KB
Volume: 11
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(10)70175-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FOLFOXIRI (folinic acid, 5-fluorouracil,

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Souglakos, J; Androulakis, N; Syrigos, K; Polyzos, A; Ziras, N; Athanasiadis, A; 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 128 KB

Phase III trial of irinotecan plus infus

Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer

✍ Ludwig Fischer von Weikersthal; Andreas Schalhorn; Martina Stauch; Detlef Quietz 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 391 KB

Irinotecan combined with fluorouracil co

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

✍ JY Douillard; D Cunningham; AD Roth; M Navarro; RD James; P Karasek; P Jandik; T 📂 Article 📅 2000 🏛 The Lancet 🌐 English ⚖ 106 KB

A triplet combination with irinotecan (C

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial

✍ Saridaki, Z; Androulakis, N; Vardakis, N; Vamvakas, L; Kabouraki, E; Kalbakis, K 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 242 KB

A phase I trial of vandetanib combined w

A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer

✍ Elwyn C. Cabebe, George A. Fisher, Branimir I. Sikic 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 112 KB

Bevacizumab in association with de Gramo

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer : A single-center phase 2 trial

✍ Bruno Vincenzi; Daniele Santini; Antonio Russo; Chiara Spoto; Olga Venditti; Sim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Abstract ## BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5‐fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. ## METHODS: The authors included 48 heavily pretreated pati